

Javier Valdivia Bautista

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4185500/publications.pdf>

Version: 2024-02-01

9
papers

5,369
citations

1162367

8
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

6928
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolomic profile of cancer stem cell-derived exosomes from patients with malignant melanoma. <i>Molecular Oncology</i> , 2021, 15, 407-428.	2.1	31
2	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. <i>Lung Cancer</i> , 2020, 150, 90-96.	0.9	18
3	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , The, 2020, 21, 645-654.	5.1	247
4	<i>Pneumocystis jirovecii</i> pneumonia in a non-small cell lung cancer patient on chemoradiotherapy: A case report. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2020, 8, 53.	0.3	6
5	Cooperative and Escaping Mechanisms between Circulating Tumor Cells and Blood Constituents. <i>Cells</i> , 2019, 8, 1382.	1.8	45
6	Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced <i>ALK</i> -rearranged non-small cell lung cancer. <i>European Respiratory Journal</i> , 2018, 51, 1702431.	3.1	32
7	Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. <i>BMC Cancer</i> , 2018, 18, 106.	1.1	9
8	Ipilimumab for advanced melanoma. <i>Melanoma Research</i> , 2014, 24, 577-583.	0.6	38
9	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943